Biosyent Inc. · TSXV:RX
Biosyent — Q4 2024 Earnings Presentation
18 slides from Biosyent's earnings presentation, Mar 13, 2025
Slide 1: BioSyent Inc. Q4/FY 2024 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q4/FY 2024 Results Results MARCH MARCH13, 13,2024 2025 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Sales, EBITDA and NIAT (Q4)
Sales, EBITDA and NIAT Quarter ended December 31st (Q4) 9,000 +6% Record Quarterly Sales +11% +7% Canadian Pharma 8,000 +223% International Pharma +35% (68%) Legacy 7,000 EBITDA / NIAT 6,000 • EBITDA Margin 5,000 Q4 2024: 25% to Sales CAD (000's) Q4 2023: 20% to Sales 4,000 • NIAT Margin 3,000 +36%
Slide 5: Sales, EBITDA and NIAT (FY)
Sales, EBITDA and NIAT Year ended December 31st (FY) +11% Sales 35,000 +13% +11% Canadian Pharma (11%) International Pharma +35% 30,000 +18% Legacy 25,000 EBITDA / NIAT • EBITDA Margin 20,000 FY 2024: 27% to Sales CAD (000's) FY 2023: 25% to Sales 15,000 • NIAT Margin +18% FY 2024: 21% to Sales 10,0
Slide 6: Q4/FY 2024 Sales Summary ($)
Q4/FY 2024 Sales Summary ($) Q4 ’24 Q4 ‘24 vs. FY ’24 FY ‘24 vs. Sales ($) Q4 ’23 (%) Sales ($) FY ’23 (%) Canadian Pharma ($) $8,546k +7% $32,931k +11% Cathejell® +4% +3% Combogesic® +39% +66% FeraMAX® Pd +7% +10% Gelclair® +26% +357% Inofolic® +92% +328% RepaGyn® (19%) +4% Tibella® (Canada) +41% +
Slide 7: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS 58 Consecutive Profitable Quarters Q4 2024 $1,613,194 $0.14 to Q4 2024 Q3 2024 $2,307,894 $0.20 $0.62 FY 2024 Q2 2024 $1,580,289 $0.13 Q1 2024 $1,768,727 $0.15 Q4 2023 $1,450,791 $0.12 Q3 2023 $2,350,900 $0.20 $0.53 FY 2023 Q2 2023 $1,483,190
Slide 8: 15 Years of Profitable Growth (and Counting!)
15 Years of Profitable Growth (and Counting!) Tibelia Global Total Company Annual Revenue 40,000 35,000 30,000 25,000 CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 *2025* f/d shares: 14,336,194 11,596,399 8 | www.biosyent.com | TSXV
Slide 9: 2024 Highlights
2024 Highlights Feb 2024: BioSyent named to 2024 TSX Venture 50 Mar/Jun/Sep/Dec 2024: Quarterly dividends of $0.045 paid (+12.5% increase vs. 2023 ) Apr 2024: FeraMAX® named #1 recommended iron supplement in Canada for ninth consecutive year Apr 2024: Extension of RepaGyn® and Proktis-M® Agr
Slide 10: 2024 Highlights (Continued)
2024 Highlights (Continued) Jun 2024: In-licensing of new endocrinology product for Canada Sept 2024: Acquisition of Tibelia® / Tibella ® (tibolone) global assets Jan – Dec 2024: 492,300 shares repurchased and cancelled under NCIB Dec 2024: NCIB Renewed for a further 12 months – 690,000 maxi
Slide 11: 2025 YTD Highlights
2025 YTD Highlights Jan 2025: Declaration of Q1 2025 dividend of $0.05/share (+11% increase vs. 2024) Jan/Feb 2025: First Tibelia® Global shipments made by BioSyent ~$0.8 million in incremental revenue YTD 2025 YTD 2025: 18,400 shares repurchased and cancelled under NCIB 11 | www.biosyent.com
Slide 12: Trade and Tariffs
Trade and Tariffs USA-Canada Tariffs / Counter-Tariffs Impact of Tariffs on Global Trade and Economies Uncertainty 12 | www.biosyent.com | TSXV: RX
Slide 13: Growth Drivers
Growth Drivers New endocrinology asset FeraMAX® Pd Platform – Life Cycle Strategy In development Tibela® / Tibella® (tibolone) - HRT agent for menopause therapy Management of symptoms of PCOS Oncology supportive care product for Oral Mucositis Acquisition and in-licensing – ongoing 13 | www.biosyent
Slide 14: Cash Balance & Return on Equity (RoE)
Cash Balance & Return on Equity (“RoE”) 30,000 25% 27,785 28,687 21% • Zero Debt 25,000 19% 26,045 • 2024 Cash from Operations 20% 17% of $8.7M 20,000 15% • 2024 NCIB share buybacks: $5.2 M CAD (000's) RoE % 15,000 10% • 2024 Dividends of $2.1M 10,000 • Dec 31/24 Working Capital of 5% $19.1M 5,000 •
Slide 15: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 15 | www.biosyent.com | TS
Slide 16: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification. • 7 new product launches in Canada since July 2020 • Tibelia® / Tibella® (tibolone) Global Acquisition in Sept 2024 Cash: Dividends $26.0M Growth & Diversification Debt: Share $0M Bu
Slide 17: Stock Information
Stock Information As at March 11, 2025 Exchange & Trading Symbol 0% TSXV: RX March 11, 2025 Closing Stock Price (CAD) (TSXV): $10.80 52 Week Hi/Low (TSXV): $12.13 / $8.24 Issued Common Shares: 11,465,816 Treasury – RSU Shares in Trust (202,199) RSUs funded Outstanding Common Shares: 11,263,617 with
Slide 18: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 18 www.biosyent.com | TSXV: RX